Physicians' Academy for Cardiovascular Education

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

Physical activity: every step counts, for everybody

3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA

Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort

3' education - Nov. 15, 2018 - JoAnn Manson, MD

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients

3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD

Not all fish oils are created equal: different compounds have different effects

3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.

Dyskalemia in real-world HF patients with different EF

Literature - Jan. 16, 2019 - Savarese G et al. - JACC HF 2019

Dyskalemia was common in HF with different risk in HF subtypes. Hyperkalemia and hypokalemia were predicted by similar variables and incident dyskalemia was associated with increased mortality.

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Similar effects of exercise training on exercise test duration and clinical outcomes in HFrEF regardless of baseline physical activity

Literature - Jan. 15, 2019 - Mediano MFF et al. - JACC: Heart Failure. 2018

In a randomized trial, a program of supervised and home-based exercise training significantly improved exercise test duration but had no effect on clinical events with similar effects across baseline physical activity tertiles in HFrEF patients.

Greater net clinical benefit of NOAC vs. warfarin in Asians with AF compared with non-Asians

Literature - Jan. 15, 2019 - Chao TF et al. - Eur Heart J 2018

A post-hoc analysis of ENGAGE AF-TIMI 48 showed comparable efficacy, favorable safety, and better net clinical outcomes with edoxaban vs. warfarin in Asians, compared to non-Asians.

Physical activity should be stressed more in T2DM, as it reduces mortality

News - Jan. 15, 2019

EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed.

Relative risk of CV events similarly increased with resting heart rate irrespective of diabetes status

Literature - Jan. 14, 2019 - Böhm M et al., - Eur Heart J 2018

In patients at high CV risk, higher absolute event rates were seen across the RHR spectrum in those with diabetes, but the relative risk increase based on RHR was similar for those with and without diabetes.

Exercise equally effective to antihypertensive medication to lower SBP in hypertensives

Literature - Jan. 14, 2019 - Naci H et al., - Br J Sports Med 2018

A network meta-analysis compared the SBP-lowering effectiveness of commonly prescribed antihypertensive treatments with structured exercise programs.

Updated recommendations on sports-participation in athletes-patients with CAD

News - Jan. 11, 2019

A position paper has been published by the Sports Cardiology section of the EAPC with updated recommendations on sports-participation in patients with CAD.

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

In the ANITSCHKOW study, 16 weeks of treatment with evolocumab in patients with elevated Lp(a) levels, did not significantly alter arterial wall inflammation, despite lowering Lp(a) by 14%.

Limited alcohol consumption associated with longer survival in older adults with incident HF

Literature - Jan. 8, 2019 - Sadhu JS et al. - JAMA Network Open. 2018

A prospective cohort study found that alcohol consumption of ≤7 drinks per week after the diagnosis of HF was associated with longer survival in adults with HF, compared to long-term abstinence.

SGLT2 inhibitor may give clinically relevant BP reductions in T2DM with nocturnal hypertension

Literature - Jan. 8, 2019 - Kario K et al., - Circulation. 2018

In the SACRA study, treatment with empagliflozin for 12 weeks was associated with reductions from baseline in nighttime, clinic, 24-hour ABP and morning HBP in T2DM with uncontrolled nocturnal hypertension.

Consensus statement: How to identify anti-inflammatory effects of lipid-lowering therapy?

News - Jan. 8, 2019

The working group on atherosclerosis and vascular biology of the European Society of Cardiology published a position paper, which provides consensus statements on how to identify anti-inflammatory effects of lipid-lowering therapy.